

References

1. Janelins M, Kesler S, Ahles T, Morrow G. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry*. 2014;26(1):102-113. doi:10.3109/09540261.2013.864260
2. Kohli S, Fisher S, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. *Cancer*. 2009;115(12):2605-2616. doi:10.1002/cncr.24287 Li Y,
3. Luo Y, Song J. Optimizing memory performance and emotional states: multi-level enhancement of adult hippocampal neurogenesis. 2023. doi:10.1016/j.conb.2023.102693
4. Pendergrass J, Targum S, Harrison J. Cognitive Impairment Associated with Cancer: A Brief Review. *Innov Clin Neurosci*. 2018;15(1-2):36-44.
5. Pereira Dias G, Hollywood R, Bevilacqua M, et al. Consequences of cancer treatments on adult hippocampal neurogenesis: implications for cognitive function and depressive symptoms. *Neuro Oncol*. 2014;16(4):476-492. doi:10.1093/neuonc/not321
6. Walker L, Wesnes K, Heys S, et al. The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. *Eur J Cancer*. 1996;32A(13):2275-2283. doi:10.1016/s0959-8049(96)00300-0
7. Wefel J, Vardy J, Ahles T, Schagen S. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. *Lancet Oncol*. 2011;12(7):703-708. doi:10.1016/S1470-2045(10)70294-1
8. Wesnes K, Edgar C, Brooker H. The Disruptions to Cognition, Everyday Function and Quality of Life in Oncology Patients: A Therapeutic Opportunity? *Neurotherapeutics*. 2010;7(3):331-339. doi:10.1016/j.nurt.2010.06.013
9. Wesnes K, McNamara C, Annas P. Norms for healthy adults aged 18-87 years for the Cognitive Drug Research System: An automated set of tests of attention, information processing and memory for use in clinical trials. *J Psychopharmacol*. 2016;30(3):263-272. doi:10.1177/0269881115625116